calendar
4,014 catalysts · 3,827 phase readout · 2,123 8k filing · 277 earnings · 172 phase 2 completion · 133 drug shortage · 109 grant
4,014 catalysts · 3,827 phase readout · 2,123 8k filing · 277 earnings · 172 phase 2 completion · 133 drug shortage · 109 grant
no tagged catalysts yet
NS grant. $429,000. PI: NAGI G AYAD
AI grant. $161,244. PI: TERESA GIL GIL
CA grant. $415,623. PI: STEPHEN J KADLECEK
AI grant. $267,000. PI: Qianxia Zhang
DK grant. $769,882. PI: Cary Ragan Boyd-Shiwarski
NR grant. $3,480,544. PI: Michelle Trivedi
ES grant. $795,869. PI: Sean M Harris
AI grant. $660,723. PI: Hongyan Guo
AI grant. $843,182. PI: Christopher F Basler
AT grant. $788,967. PI: ADAM L. Halberstadt
Sponsor: EXTROVIS. Form: SOLUTION. Route: INTRAVENOUS
Sponsor: NOVARTIS PHARMS CORP. Form: INJECTABLE. Route: INJECTION
Sponsor: NOVARTIS PHARMS CORP. Form: INJECTABLE. Route: INJECTION
Sponsor: NOVARTIS PHARMS CORP. Form: INJECTABLE. Route: INJECTION
Sponsor: NOVARTIS PHARMS CORP. Form: INJECTABLE. Route: INJECTION
Sponsor: QUAGEN. Form: SYRUP. Route: ORAL
Sponsor: YICHANG HUMANWELL. Form: TABLET, EXTENDED RELEASE. Route: ORAL
Sponsor: GLENMARK SPECLT. Form: CREAM. Route: TOPICAL
Sponsor: MARKSANS PHARMA. Form: CAPSULE, DELAYED RELEASE. Route: ORAL
Sponsor: GLENMARK PHARMS LTD. Form: TABLET, FOR SUSPENSION. Route: ORAL
Sponsor: GLENMARK PHARMS LTD. Form: TABLET, FOR SUSPENSION. Route: ORAL
Sponsor: IMPAX LABS. Form: CAPSULE. Route: ORAL
Sponsor: IMPAX LABS. Form: CAPSULE. Route: ORAL
AI grant. $209,758. PI: Paul K Drain
AT grant. $601,259. PI: Ashley E. Mason
NS grant. $568,920. PI: Theresa Currier Thomas
CA grant. $496,357. PI: DANIEL J BRAT
AT grant. $170,640. PI: Julia E. Hooker
AI grant. $210,302. PI: William Evan Johnson
DK grant. $231,000. PI: Roger D. Cone
NS grant. $230,562. PI: Thuy Nguyen
ES grant. $117,747. PI: Rebecca Sugrue
Sponsor: AUROBINDO PHARMA LTD. Form: TABLET. Route: ORAL
Sponsor: ABBVIE. Form: IMPLANT. Route: INTRAVITREAL
Sponsor: ACCORD HLTHCARE. Form: TABLET, EXTENDED RELEASE. Route: ORAL
Sponsor: AUROBINDO PHARMA. Form: CAPSULE. Route: ORAL
Sponsor: NOVARTIS. Form: TABLET. Route: ORAL
Sponsor: University of Alberta. Phase: . Conditions: Low Back Pain
Sponsor: Beijing Sport University. Phase: NA. Conditions: Patellofemoral Pain
Sponsor: Definium Therapeutics US, Inc.. Phase: PHASE3. Conditions: Major Depressive Disorder
Sponsor: M.D. Anderson Cancer Center. Phase: PHASE2. Conditions: Unresectable Melanoma
Sponsor: The University of Queensland. Phase: NA. Conditions: Blood Culture Contamination, Infection
Sponsor: Mayo Clinic. Phase: . Conditions: Spontaneous Coronary Artery Dissection
Sponsor: Riphah International University. Phase: NA. Conditions: Adhesive Capsulitis of the Shoulder
Sponsor: October 6 University. Phase: NA. Conditions: Cerebral Palsy
Sponsor: Liverpool School of Tropical Medicine. Phase: NA. Conditions: Crimean-Congo Haemorrhagic Fever
Sponsor: Eilean Therapeutics AU Pty Ltd. Phase: PHASE1. Conditions: Healthy Volunteers
Sponsor: Chandan Sen. Phase: NA. Conditions: Wound Heal, Wound Infection, Wound Healing Delayed, Wound of Skin, Infections
Sponsor: National Institute of Mental Health (NIMH). Phase: . Conditions: Neuropsychiatric Disorder, Neurological Disorder, Neurodevelopmental Disorder, Sleep
Sponsor: University of Washington. Phase: NA. Conditions: Mental Health Disorder